Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.A European patent has been granted to biopharmaceutical development company BioLineRx' BL-1020's composition and its use for the treatment of schizophrenia. The patent will be valid until 29 September 2022.
Subscribe to our email newsletter
Notice of allowance has been granted to member patents of this family in the US, Japan, India, China, Korea, Mexico, Israel and Australia.
BL-1020 is a novel, first in class, oral therapeutic for schizophrenia, and according to pre-clinical and clinical studies BL-1020 is effective at treating schizophrenia symptoms and has a good safety profile.
BioLineRx CEO Kinneret Savitsky said the company is extremely pleased at receiving approval for the European Patent covering BL-1020 which joins the broad protection the company has already received in other territories, securing a broad basis for its future commercial operations.
"We believe this represents significant further progress in the development and commercialization of BL-1020," Savitsky added.
"BL-1020 has previously demonstrated improved cognitive function in schizophrenia patients, and we are currently conducting the CLARITY clinical trial, which has validation of BL-1020’s cognition enhancement as its primary objective. We expect to obtain results during mid-2013."